Imvexxy
Imvexxy is an ultra-low-dose estradiol softgel insert placed vaginally, FDA-approved to treat moderate to severe dyspareunia caused by menopause.
How it works
Imvexxy delivers estradiol in a softgel insert format — no applicator is needed; the small insert is placed by hand. It is FDA-approved specifically for dyspareunia (painful intercourse) due to menopause, and the ultra-low estradiol doses (4 mcg and 10 mcg strengths) produce minimal systemic absorption, keeping serum estradiol within postmenopausal ranges. Like Vagifem, it is sometimes used in breast cancer survivors after discussion with their oncologist, though this requires individual clinical judgment. The dosing schedule follows the same pattern as other vaginal estradiol: daily for an initial two-week period, then twice weekly.
Beyond dyspareunia, Imvexxy addresses the broader genitourinary syndrome of menopause: vaginal dryness, thinning, and urinary symptoms. Tissue improvement is gradual — four to twelve weeks is a typical response timeline. The softgel format is often more comfortable for insertion than applicator-based tablets for people with significant atrophic changes.
How to track Imvexxy
- Dyspareunia (painful intercourse) — the primary FDA-labeled indication; track both frequency and severity.
- Vaginal dryness and discomfort level — a broader symptom measure that captures daily quality of life beyond sexual activity.
- Insertion comfort — the no-applicator format is a practical distinguishing feature; tracking whether insertion is comfortable reveals tissue condition improvement over time.
- Application schedule adherence — loading vs. maintenance phases should be noted in the log.
- Urinary urgency, frequency, or recurrent UTIs as secondary response measures.
- Track dyspareunia from the start even if you are not currently sexually active — having a baseline vaginal discomfort rating shows your trajectory regardless of that variable.
- Rate insertion comfort as a separate item — the no-applicator format can be an advantage for people with significant tissue atrophy, and tracking it separately shows whether that dimension is improving.
- Note which dose strength you are using (4 mcg or 10 mcg) in your log — if your physician adjusts the strength, having the dose alongside symptom data makes the comparison clean.
- Log whether you are in the loading phase or maintenance phase at any given time — the expected pace of improvement differs between phases.
- Log urinary symptoms separately from vaginal symptoms — both can improve with local estrogen, but on potentially different timelines.
Questions to ask your physician
- My dyspareunia severity rating before starting was [X]. At [N] weeks on Imvexxy, my current rating is [Y]. Is that consistent with the expected response timeline?
- I've been logging general vaginal dryness at [rating] — it has [improved/partially improved] alongside dyspareunia. Are they expected to respond at the same rate?
- My insertion comfort has [improved/not improved] over [N] weeks. Does that level of change suggest the tissue is responding, or would a different dose or formulation be more appropriate?
- I've also been tracking urinary urgency — here is the pattern over [N] weeks. Is the urinary improvement within the expected range for vaginal estradiol?